close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by ReShape Lifesciences Inc

< Previous 1 2 Next >
News headline image
ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences Announces 1-for-25 Reverse Stock Split
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Receives NIH Supplementary Grant with the University of Southern California’s Center for Autonomic Nerve Recording and Stimulation Systems (CARSS) to Further Develop Next-Generation Electrodes for ReShape’s Proprietary Diabetes
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences Announces 1-for-58 Reverse Stock Split
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Reports Second Quarter Ended June 30, 2024 Financial Results and Provides Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate Update
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
News headline image
ReShape Lifesciences® Enters Into Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
From ReShape Lifesciences Inc
Via GlobeNewswire
Tickers RSLS
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.